ZOLL Announces Successful Bid to Acquire Vyaire Medical

“Respiratory care has been central to ZOLL’s business strategy for many years,” said Jon Rennert, CEO of ZOLL. “If the acquisition is successfully completed, adding Vyaire’s ventilators to ZOLL’s product portfolio will enhance our ability to serve a broader range of clinicians and patients.”

ZOLL, an Asahi Kasei company that manufactures medical devices and related software solutions, announced today that it is the winning bidder in an auction to acquire Vyaire Medical’s ventilator business as part of Vyaire’s Chapter 11 bankruptcy proceedings. Completion of the acquisition is subject to court approval at a sale hearing and dependent on a successful closing that is anticipated to occur in the coming weeks.

ZOLL is a global leader in acute critical care and related software and diagnostic tools, and its solutions are used worldwide to diagnose and treat patients suffering from serious cardiopulmonary and respiratory conditions. Since 2014, ZOLL has manufactured ventilation devices and accessories designed for the transport of critically ill patients.

“Respiratory care has been central to ZOLL’s business strategy for many years,” said Jon Rennert, CEO of ZOLL. “If the acquisition is successfully completed, adding Vyaire’s ventilators to ZOLL’s product portfolio will enhance our ability to serve a broader range of clinicians and patients.”

Until new ownership is final, Vyaire ventilator customers should continue to contact Vyaire (for details visit https://www.vyaire.com/contact-us).

Additional Background

On June 10, 2024, Vyaire Medical announced it had voluntarily filed for Chapter 11 bankruptcy protection in the U.S. The Chapter 11 filing allowed Vyaire to continue to operate while seeking to sell its business units, including the Vyaire ventilation business. Since filing for bankruptcy, day-to-day operations at Vyaire have continued with little interruption, and Vyaire has continued to serve its ventilator customers and maintain the team needed to operate safely and efficiently.

More

Artificial Intelligence Tools Make Education Materials More Patient Friendly

“Our study shows that widely used large language models have the potential to transform patient education materials into more readable content, which is essential for patient empowerment and better health outcomes,” said Study senior author Jonah Feldman, MD, medical director of transformation and informatics at NYU Langone.

CorWave Completes 6-Month In Vivo Study for Clinical Trials Initiation

In vivo studies demonstrated the pump’s successful operation for a period of up to six months. Additionally, nine chronic ovine implants were conducted for 60 days with no device failure or sign of thrombosis at explant. These significant milestones mark the final stage of CorWave’s preclinical development, paving the way for its First-In-Human study.